These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10652908)

  • 1. Hypertension and the kidneys--inter-relationship and therapeutic approach.
    Sharma BK; Sharma N; Jain S
    J Indian Med Assoc; 1999 Mar; 97(3):91-5; 105. PubMed ID: 10652908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium channel blockers: effects on progressive renal disease.
    Zucchelli P; Zuccalà A; Gaggi R
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):94-7. PubMed ID: 2024684
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic strategy for progressive renal disease].
    Hayashi K; Ozawa Y; Tokuyama H
    Nihon Rinsho; 2001 May; 59(5):955-60. PubMed ID: 11391998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ACE-inhibitors in renal protection].
    Barna I
    Orv Hetil; 2006 Jun; 147(22):1019-23. PubMed ID: 16913091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers and nephroprotection.
    Ungar A; Di Serio C; Lambertucci L; Monami M; Masotti G
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):31-9. PubMed ID: 16640171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal mechanisms of angiotensin II-induced hypertension.
    Granger JP; Schnackenberg CG
    Semin Nephrol; 2000 Sep; 20(5):417-25. PubMed ID: 11022893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypertension and the kidneys].
    Monhart V
    Vnitr Lek; 1999 Nov; 45(11):631-5. PubMed ID: 10951852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.
    Swales P; Williams B
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):79-89. PubMed ID: 12228847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of angiotensin converting enzyme inhibitors in nephrology].
    Stefanović V; Ivić M; Bogićević M
    Srp Arh Celok Lek; 1994; 122(7-8):228-30. PubMed ID: 17974394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renovascular hypertension: is it only the top of the iceberg?].
    Lewandowski J
    Pol Merkur Lekarski; 2003 Oct; 15(88):371-5; discussion 375-6. PubMed ID: 14974369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blockers: do they offer renal protection?
    Reams GP
    J Hum Hypertens; 1993 Jun; 7(3):211-9. PubMed ID: 8345486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review of antihypertensive agents providing renal protection.
    Kalus JS; White CM
    Conn Med; 2001 Oct; 65(10):587-91. PubMed ID: 11702517
    [No Abstract]   [Full Text] [Related]  

  • 20. Kidney and hypertension-causes. Update 2003.
    Ritz E; Adamczak M; Zeier M
    Herz; 2003 Dec; 28(8):663-7. PubMed ID: 14689099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.